Vazyme Biotech Ties Up With BGI Genomics to Develop Genetic Products

MT Newswires Live

2025/03/10

Nanjing Vazyme Biotech (SHA:688105) partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.

Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.

The agreement is valid until March 5, 2030, the Chinese biotechnology company said.

Vazyme's shares closed over 2% higher.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2518972402"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518972402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2518972402?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-10 16:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518972402","market":"sh","top_or_hot":-1,"title":"Vazyme Biotech Ties Up With BGI Genomics to Develop Genetic Products","media":"MT Newswires Live","content":"<html><body><p> Nanjing Vazyme Biotech (SHA:688105) partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.</p><p>Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.</p><p>The agreement is valid until March 5, 2030, the Chinese biotechnology company said.</p><p>Vazyme's shares closed over 2% higher.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vazyme Biotech Ties Up With BGI Genomics to Develop Genetic Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVazyme Biotech Ties Up With BGI Genomics to Develop Genetic Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-10 16:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nanjing Vazyme Biotech (SHA:688105) partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.</p><p>Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.</p><p>The agreement is valid until March 5, 2030, the Chinese biotechnology company said.</p><p>Vazyme's shares closed over 2% higher.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688105","symbol_name":"诺唯赞","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2518972402","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518972402","pubTimestamp":1741594745,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nanjing Vazyme Biotech  partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.The agreement is valid until March 5, 2030, the Chinese biotechnology company said.Vazyme's shares closed over 2% higher.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688105":"诺唯赞","BK4094":"服装零售","BK0216":"研究试验","BGI":"Birks Group Inc."},"translate_title":"Vazyme Biotech与BGI Genomics合作开发基因产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688105":0.6,"BGI":0.6},"content_text":"Nanjing Vazyme Biotech (SHA:688105) partnered with Shenzhen BGI Genomics to develop genetic products, according to a Shanghai Stock Exchange filing on Saturday.Both parties signed a five-year agreement to develop reproductive genetics and other genetic projects that will prevent tumors, dementia and other diseases.The agreement is valid until March 5, 2030, the Chinese biotechnology company said.Vazyme's shares closed over 2% higher.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}